Bioavailability of a new generic formulation of imatinib mesylate 400mg tablets versus glivec in healthy male adult volunteers

Journal of Bioequivalence and Bioavailability

Volumn 3, Issue 7, 2011, Pages 161-164

  Jawhari, Dalia ^a   Alswisi, Mahmoud ^a   Ghannam, Mahmoud ^a  

^a BSc Pharmacy ^*  (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; IMATINIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; POLYDIPSIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE;

EID: 80052361457     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000077     Document Type: Article

References (16)

1. Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557.
2. Savage DG, Antman KH (2002) Imatinib Mesylate - A New Oral Targeted Therapy. N Engl J Med 346: 683-693.
3. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of Imatinib. Clinical Pharmacokinetics 44: 879-894.
4. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM (1999) The Biology of Chronic Myeloid Leukemia. The New England Journal Of Medicine 341: 164-172.
5. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, et al. (2004) Pharmacokinetics and pharmacodynamics of Imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942.
6. Kubota T (2006) Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol 11: 184-189.
7. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, et al. (2008) Innovative Therapies with Children with Cancer European consortium. Population pharmacokinetics and pharmacogenetics of Imatinib in children and adults. Clin Cancer Res 14: 7102-7109.
8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, (2001) Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med 344: 1031-1037.
9. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, et al. (2005) Metabolism and disposition of Imatinib mesylate in healthy volunteers. Drug Metab Dispos 33: 1503-1512.
10. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, et al. (2004) Absolute bioavailability of Imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44: 158-162.
11. Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, et al. (2004) Bioequivalence, safety, and tolerability of Imatinib tablets compared with capsules. Cancer Chemother Pharmacol 53: 433-438.
12. van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35: 692-706.
13. van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, et al. (2007) Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of Imatinib. Clin Cancer Res 13: 7394-7400.
14. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, et al. (2004) Pharmacokinetic interaction between ketoconazole and Imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54: 290-294.
15. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, et al. (2003) Effect of rifampicin on the pharmacokinetics of Imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53: 102-106.
16. Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodríguez P, Márquez S, et al. (2009) Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther 31: 2224-2232.